Cline Scientific receives Decision to Grant for StemCART in Europe

Cline Scientific has received a Decision to Grant from the European Patent Office (EPO) related to the StemCART patent.

The patent application is titled "A method for providing a cartilage implant with chondrocytes". The decision will take effect from the 14th of June 2023.

The notice of allowance for this patent was received from EPO and a press release was sent out in April.

More about StemCART

StemCART is a preclinical Advanced Therapy Medicinal Product (ATMP) that aims to revolutionize the treatment of cartilage damage for patients worldwide.

For more information, please contact:

Hanne Evenbratt, Interim CEO and VP – Research & Development

Email: hanne.evenbratt@clinescientific.com

Phone: +46 704 88 79 23

Cline Scientific AB (publ)                                                 Phone: 031-387 55 55
Argongatan 2 C                                                                   Email: info@clinescientific.com
431 53  MÖLNDAL                                                              Website: www.clinescientific.com

About Cline Scientific
Cline Scientific develops advanced cancer diagnostics and regenerative medicine treatments. Cline’s unique patented surface nanotechnology provides solutions to critical challenges for cell-based products and process in Life Science. Cline is driving two projects through to a clinical stage, StemCART - a stem cell therapy for joint repair, and CellRACE- a cancer diagnostic to predict metastasis.